Scienture Holdings (SCNX) Common Equity (2013 - 2026)
Scienture Holdings' (SCNX) quarterly Common Equity came in at $64.1 million in Q2 2026, down 17.67% year-over-year from $77.9 million in Q2 2025, and down 4.07% quarter-over-quarter from $66.8 million in Q1 2026.
Analysis
Scienture Holdings (SCNX) Common Equity (2013 - 2026) Analysis & Trends
Scienture Holdings has disclosed Common Equity across 14 years of filings, most recently posting $64.1 million for Q2 2026.
- In Q2 2026, Common Equity fell 17.67% year-over-year to $64.1 million; the TTM figure through Jun 2026 stood at $64.1 million (down 17.67% YoY), while the FY2025 annual figure was $70.1 million, down 29.88% from the prior year.
- Common Equity came in at $64.1 million for Q2 2026 at Scienture Holdings, down from $66.8 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $100.0 million in Q1 2023 to a low of -$1.3 million in Q2 2023.
- Average Common Equity over 5 years is $43.4 million, with a median of $38.9 million recorded in 2024.
- Year-over-year, Common Equity sank 171.74% in 2023 and jumped 14479.46% in 2024.
- Over 5 years, Common Equity stood at $342867.0 in 2022, then jumped by 58.18% to $542353.0 in 2023, then jumped by 14479.46% to $79.1 million in 2024, then declined by 11.32% to $70.1 million in 2025, then slipped by 8.58% to $64.1 million in 2026.
- Per Business Quant data, the three most recent Common Equity figures were $64.1 million in Q2 2026, $66.8 million in Q1 2026, and $70.1 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | 7.76 Bn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | 14.26 Bn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | 4.08 Bn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 33.02 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | -1.77 Bn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | 597.21 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | -191.48 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 768.16 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | 42.44 Mn |
| 10 | Scienture Holdings | 15.19 Mn | 15.19 Mn | 335,779.00 | 64.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 64.10 Mn |
| Mar 31, 2026 | 66.82 Mn |
| Dec 31, 2025 | 70.12 Mn |
| Sep 30, 2025 | 100.00 Mn |
| Jun 30, 2025 | 77.86 Mn |
| Mar 31, 2025 | 81.16 Mn |
| Dec 31, 2024 | 79.07 Mn |
| Sep 30, 2024 | 100.00 Mn |
| Jun 30, 2024 | 11.79 Mn |
| Mar 31, 2024 | 13.62 Mn |
| Dec 31, 2023 | 542,353.00 |
| Sep 30, 2023 | 11.56 Mn |
| Jun 30, 2023 | -1.29 Mn |
| Mar 31, 2023 | 100.00 Mn |
| Dec 31, 2022 | 342,867.00 |
| Sep 30, 2022 | 1.36 Mn |
| Jun 30, 2022 | 1.80 Mn |
| Mar 31, 2022 | 2.89 Mn |
| Dec 31, 2021 | 3.77 Mn |
| Sep 30, 2021 | 4.62 Mn |